LDS/Medical Tests/MI Cancer Seek® Companion Diagnostic Molecular Profiling Test for Solid Tumors

MI Cancer Seek® Companion Diagnostic Molecular Profiling Test for Solid Tumors

MI Cancer Seek is a next-generation sequencing (NGS) based in vitro diagnostic (IVD) device using total nucleic acid (TNA) isolated from formalin-fixed paraffin-embedded (FFPE) tumor tissue specimens for the detection of single nucleotide variants (SNVs) and insertions and deletions (indels) in 228 genes, microsatellite instability (MSI), tumor mutational burden (TMB) in patients with previously diagnosed solid tumors, and copy number amplification (CNA) in one gene in patients with breast cancer. MI Cancer Seek® is the first and only simultaneous Whole Exome Sequencing (WES) and Whole Transcriptome Sequencing (WTS)-based assay with FDA-approved CDx indications for molecular profiling of solid tumors.

MI Cancer Seek is intended as a companion diagnostic to identify patients who may benefit from treatment with the targeted therapies listed in the Companion Diagnostic Indications table, in accordance with the approved therapeutic product labeling. Additionally, MI Cancer Seek is intended to provide tumor mutational profiling to be used by qualified healthcare professionals in accordance with professional oncology guidelines for cancer patients with previously diagnosed solid malignant neoplasms. Genomic findings other than those listed in the Companion Diagnostic Indications table are not prescriptive or conclusive for labeled use of any specific therapeutic product.

IndicationBiomarkerTherapy
Breast CancerPIK3CA (C420R; E542K; E545A; E545D [1635G>T only]; E545G; E545K; Q546E; Q546R; H1047L; H1047R; H1047Y)PIQRAY® (alpelisib)
Colorectal Cancer (CRC)KRAS wild-type (no mutations in exons 2, 3, 4) and NRAS wild-type (no mutations in exons 2, 3, 4)VECTIBIX® (panitumumab)
Colorectal Cancer (CRC)BRAF V600EBRAFTOVI® (encorafenib) + ERBITUX® (cetuximab)
MelanomaBRAF V600EBRAF inhibitors (FDA-approved)*
MelanomaBRAF V600E or V600KMEKINIST® (trametinib) or FDA-approved **BRAF/MEK inhibitor combinations***
Non-Small Cell Lung Cancer (NSCLC)EGFR exon 19 deletions or exon 21 L858R alterations**FDA-approved EGFR tyrosine kinase inhibitors***
Solid TumorsMSI-HKEYTRUDA® (pembrolizumab), JEMPERLI® (dostarlimab-gxly)
Endometrial Carcinoma (Not MSI-H)Not MSI-HKEYTRUDA® (pembrolizumab) + LENVIMA® (lenvatinib)

This test is provided by Caris Life Sciences, https://www.carislifesciences.com/physicians/physician-tests/mi-cancer-seek/

  • Companion diagnostic (CDx) to identify patients who may benefit from cancer treatment with the targeted therapies as shown in the table above
  • To provide tumor mutational profiling to be used in accordance with professional oncology guidelines for cancer patients with previously diagnosed solid tumors

Positive: A clinically significant genomic alteration or biomarker is detected that may inform targeted therapy, immunotherapy, or trial selection.

Negative: No actionable genomic alterations detected. Absence of detected biomarkers does not exclude the presence of subclonal, low-frequency, or non-covered alterations.
Results must be interpreted in conjunction with clinical, radiologic, and histopathologic findings.

Not applicable (qualitative companion diagnostic assay)

Hybrid-capture next-generation sequencing (DNA and RNA) with bioinformatic analysis for single-nucleotide variants, insertions/deletions, gene fusions, copy number alterations, MSI, and TMB assessment.

FFPE tumor tissue (biopsy or resection block or unstained slides).

Stability

Room temperature for longer period.

PD-L1 IHC or repeat testing using alternate specimen when tumor content is inadequate.
1-3 weeks.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login